Natriuretic peptide family. Options for use in outpatient practice
https://doi.org/10.21518/2079-701X-2014-2-77-81
Abstract
Heart failure associated with high mortality, disability of the population and representing an economic burden for the society, is one of the major challenges in the modern health care [5]. A 10-year population observation demonstrated that the incidence of chronic heart failure (CHF) grows by an average of 1.2 people per 1 thousand per year. In Russia, CHF was diagnosed in 92% of patients admitted to cardiology hospitals in 2003 [9]. The main reason for the increasing number of CHF patients and duration of hospital stay is late detection of the disease.
About the Authors
S. V. Ivanova
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow
Russian Federation
Russian Federation
E. A. Nesterova
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow
Russian Federation
Russian Federation
References
1. Агеев Ф.Т., Даниелян М.О., Мареев Ю.В., Беленков Ю.Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Сердечная недостаточность, 2004, 5 (1): 4-7.
2. Борисов С.Н, Гендлин Г.Е., Сторожаков Г.И. Исследование N-терминального пептидного фрагмента мозгового натрийуретического пептида в диагностике ХСН с сохраненной систолической функцией левого желудочка. Сердечная недостаточность, 2011, 12 (6(68)): 344-349.
3. Елисеев О.М. Натрийуретические пептиды. Эволюция знаний. Тер. архив, 2003, 9: 40-45.
4. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность, 2010, 11 (1(57)): 3-62.
5. Преображенский Д.В. Сидоренко Б.А. Диагностика и лечения хронической сердечной недостаточности. М., 2004.
6. BNP. ADVIA Centaur Assay Manual [product insert]. BayerHealtcare LLC, 2003.
7. Buckley M, Marcus N, Yacoub M, Singer D. Prolonged stability of brain natriuretic peptide: importance for-invasive assessment of cardiac function in clinical practice. Clin Sci, 1998, 95: 235-239.
8. Choe H, Yoo BS, Ryu HY, et al. The early changing pattern of the B-type natriuretic peptide concentration and its significance as a prognostic marker after acute myocardial infarction. Korean CircJ, 2006, 36: 526-34.
9. Cleiand JG, Swedberg K, Follath F et al. The Euro Heart survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J., 2003, 24 (5):442-463.
10. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol, 2000, 35: 569-82.
11. Cowie M, Struthers A, Wood D et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet, 1997. 350: 1349-1353.
12. Cragill RL, Barr CS, Coutie WJ et al. C-type natriuretic peptide in cor pulmonale and in congestive heart failure. Thorax, 1994, 49: 1247-1249.
13. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation, 1990, 82: 1724-1729.
14. Fuat A, Murphy JJ, Hungin AP, Curry J, Mehrzad AA, Hetherington A, Johnston JI, Smellie WS, Duffy V, Cawley P. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract, 2006, 56: 327-333.
15. Gobinet-Georges A, Valli N, Filliatre H, Dubernet M, Dedeystere O, Bordenave O. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med, 2000, 38: 519-523.
16. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of cardiology. Eur Heart J, 2001, 22: 1527-1560.
17. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of cardiology. European Heart Journal, 2012, 33: 1787-1847.
18. Kazanegra R, Van Cheng, Garcia A et al. A rapid test for B-type natriuretic peptide correlates with filling wedge pressure in patients treated for decom-pensated heart failure: a pilot study. J Car Fail, 2001,7: 21-29.
19. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Nat Acad Sci, 2001, 98: 2703-2706.
20. Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, Gardetto N, Garcia A, DeMaria A, Maisel AS. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med, 2001, 111: 274-279.
21. Lee KH, Kim JY, Koh SB et al. N-Terminal Pro-B-type Natriuretic Peptide Levels in the Korean General Population. Print ISSN 1738-5520 / On-line ISSN 1738-5555Copyright © 2010 The Korean Society of Cardiology.
22. Lerman A, Gibbons R, Rodeheffer R et al. Circulatory N-terminal ANP as a marker for symptomless LV dysfunction. Lancet, 1993, 341: 1105-1109.
23. Luchner A, Burnett JC Jr, Jougasaki M et al. Evaluation of brain natriuretic peptide as a marker of left ventricular dysfunction and hypertrophy in the population. JHypertens, 2000, 18: 1121-1128.
24. Maeda K., Tsutamoto T., Wada A. et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end diastolic pressure in patients with symptomatic left ventricular dysfunction. // Am Heart J 1998;135:825-832.
25. Matsukawa N., Grzesik W.J., Takahashi N. et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. // Proc Nat Acad Sci USA 1999;96:7403-7408.
26. Morrison L.K., Harrison A., Krishnaswamy P. et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. // J Am Coll Cardiol 2002;39:202-209.
27. Motwani J., McAlpine H., Kennedy N., Struthers A. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. // Lancet 1993; 341:1109-1113.
28. Mukoyama M., Nakao K., Hosoda K. etal. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. // J Clin Invest 1991;87:1402-1412.
29. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. // J Hypertens 1992;10:907-12.
30. Ogawa Y, Nakao K, Mukoyama M, et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. // Circ Res 1991; 69: 491-500.
31. proBNP. Elecsys Systems1010/2010/Modular analytics E170 [product insert]. Roche Diagnostics; 2001.
32. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. // J Am Coll Cardiol 2002;40:976-82.
33. Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. // J Am Coll Cardiol 2000;35:1256-62.
34. Shih- Hung Tsai, Yen-Yue Lin, Shi-Jye Chu, Ching-Wang Hsu, Shu-Meng Cheng Interpretation and Use of Natriuretic Peptides in Non-Congestive Heart Failure Settings // Yonsei Med J 51(2):151-163, 2010.
35. Shionoria BNP. Quantative immonoradiometric assay kit for the determination of human brain (B-type) natriuretic peptide in plasma [product insert]. Osaka, Japan; Shionogi&Co., LTD; 2002.
36. Silver M.A., et al. BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular Diseases. // Congestive Heart Failure. − 2004. − Vol. 10. − P. 1-28.
37. Struijker-Boudier HA, Smits JF, De Mey JG. Pharmacology of cardiac and vascular remodeling. // Annu Rev Pharmacol Toxicol 1995; 35: 509-39.
38. Sudoh T., Kangawa K., Matsuo H. A natriureric peptide in porcine brain // Nature.-1988.-№322.-P.78-81.
39. Sutton TM, Stewart RA, Gerber IL, et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. // J Am Coll Cardiol 2003;41:2280-7.
40. Swynghedauw B. Molecular mechanisms of myocardial remodeling. // Physiol Rev 1999; 79: 215-62.
41. TuenenburgA. E.f van Veldhuisen D.J., Boomsna F. et al. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus with sinus rhythm. // Am J Cardiol 1998;81:1207-1210.
42. Van den Berg М.Р., van Veldhuisen D.J., Tjeersma G. et al. Atrial fibrillate//ion causes depletion of atrial natriuretic peptide in patients with advanced heart failure. // Eur Heart J 2000;21:Abstr.Suppl:133.
43. Vanderheyden M., Bartunec J. Brain and other natriuretic peptides: molecular aspects// Eur J of Heart Fail.-2004.-№3- P.261-267.
44. Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. // Circulation 2003;108:13-6.
45. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. // Circulation 2004;109:594-600.
Review
For citations:
Ivanova SV, Nesterova EA. Natriuretic peptide family. Options for use in outpatient practice. Meditsinskiy sovet = Medical Council. 2014;(2):77-81. (In Russ.) https://doi.org/10.21518/2079-701X-2014-2-77-81
Views:
471
Email this article 